NYMX Nymox Pharmaceutical Corporation

3
-0.06  -2%
Previous Close 3.06
Open 3.1
Price To Book 37.5
Market Cap 209,906,118
Shares 69,968,706
Volume 120,404
Short Ratio
Av. Daily Volume 135,305
Stock charts supplied by TradingView

NewsSee all news

  1. Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology

    HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report a new peer review research report has been published on experimental studies of the

  2. Nymox Reports on Newly Issued Patents and Corporate Developments

    HASBROUCK HEIGHTS, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Data released February 2016 met endpoint
NX-1207 long-term NX03-0040 trial
Low grade localized prostate cancer
NDA filing planned.
NX-1207 Fexapotide
BPH

Latest News

  1. Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology

    HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report a new peer review research report has been published on experimental studies of the

  2. Nymox Reports on Newly Issued Patents and Corporate Developments

    HASBROUCK HEIGHTS, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United